In order to provide a faster, more comprehensive and cost-effective assay for NSNHL mutations, the HHL APEX (Hereditary Hearing Loss Arrayed Primer Extension) microarray was developed [7].
Such future modification of the flexible configuration of the Hereditary Hearing Loss Arrayed Primer Extension microarray would improve its impact as a diagnostic tool.
The more comprehensive Hereditary Hearing Loss Arrayed Primer Extension microarray enables analysis of 198 mutations across eight genes (GJB2, GJB6, GJB3, GJA1, SLC26A4, SLC26A5, MTRNR1 and MTTS1) in a single test.
This study presents the results from hearing loss arrays developed in two different research facilities and highlights some of the approaches we adopted to enhance the applicability of the arrays in a clinical setting.
We present results from hearing loss arrays developed in two different research facilities and highlight some of the approaches we adopted to enhance the applicability of resequencing arrays in a clinical setting.
Cancers evaluated for biallelic loss with array technology include prostate (SNP array) [ 25, 27], B-cell lymphomas (CGH array) [ 28], and B-cell chronic lymphocytic leukemia (SNP array) [ 29].
Unfortunately, the gains over the single-cell schemes were marginal, partly due to the loss in array gain of B in multi-cell ZF, instead of K as with single-cell ZF.
The whole information of the two parallel ULAs is fully utilized by changing the reference element to reconstruct the two new cumulants-based matrices, which avoids the loss of array physical aperture.
The reason is that the proposed algorithm utilizes the whole ULAs to estimate the source signals, which avoids the loss of array physical aperture and achieves excellent decoherence performance.
The information of the whole two subarrays elements is fully utilized to reconstruct two new matrices by changing the reference element, which can achieve the decorrelation of the coherent signals as well as avoid the loss of array aperture.
